Estradiol benzoate/testosterone isobutyrate

Testosterone Isobutyrate (also known as Agovirin-Depot and Perandren M) is an androgen and anabolic steroid medication. It is a testosterone ester used for treating conditions such as low testosterone levels in men and delayed puberty in boys. This medication is currently available only in the Czech Republic.

Etymology[edit | edit source]

The term "Testosterone Isobutyrate" is derived from its chemical structure. "Testosterone" is the primary male sex hormone, "iso" refers to the isomer structure, and "butyrate" refers to the butyric acid ester.

Medical Uses[edit | edit source]

Testosterone Isobutyrate is used in the treatment of conditions related to low testosterone levels in men. These conditions may include hypogonadism, a condition where the body does not produce enough testosterone. It is also used in the treatment of delayed puberty in boys.

Pharmacology[edit | edit source]

As an androgen and anabolic steroid, Testosterone Isobutyrate works by supplementing or replacing the testosterone that is naturally produced in the body. Testosterone is a hormone that is necessary for normal growth and development of male sex organs and for the maintenance of secondary sex characteristics.

Side Effects[edit | edit source]

Like all medications, Testosterone Isobutyrate can cause side effects. These may include acne, hair loss, and an increase in body hair. More serious side effects can include liver damage, heart disease, and mental health problems such as aggression and depression.

Availability[edit | edit source]

Testosterone Isobutyrate is currently available only in the Czech Republic, where it is sold under the brand names Agovirin-Depot and Perandren M.

See Also[edit | edit source]

Estradiol benzoate/testosterone isobutyrate Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.